Catalent Inc
NYSE:CTLT

Watchlist Manager
Catalent Inc Logo
Catalent Inc
NYSE:CTLT
Watchlist
Price: 63.48 USD Market Closed
Market Cap: 11.5B USD

Net Margin
Catalent Inc

-9.3%
Current
-5%
Average
5.1%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-9.3%
=
Net Income
-413m
/
Revenue
4.4B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Catalent Inc
NYSE:CTLT
11.5B USD
-9%
US
Eli Lilly and Co
NYSE:LLY
700.7B USD
23%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
372.4B USD
24%
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK
35%
CH
Roche Holding AG
SIX:ROG
210.7B CHF
14%
CH
Novartis AG
SIX:NOVN
185.7B CHF
24%
UK
AstraZeneca PLC
LSE:AZN
164B GBP
14%
US
Merck & Co Inc
NYSE:MRK
190.2B USD
27%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
-126%
US
Pfizer Inc
NYSE:PFE
132.8B USD
13%

Catalent Inc
Glance View

Economic Moat
None
Market Cap
11.5B USD
Industry
Pharmaceuticals

In the intricate world of pharmaceuticals, Catalent Inc. stands out as a critical player, quietly orchestrating the development and delivery of drugs that impact lives globally. Founded in 2007, Catalent has carved a niche in the field through its commitment to advanced drug delivery technologies and supply chain services. As a contract development and manufacturing organization (CDMO), the company offers a suite of services to pharmaceutical and biotechnology firms, including drug formulation and delivery optimization, biologics development, and clinical supply services. With over 30 facilities worldwide, it acts as a pivotal partner to firms seeking to enhance the effectiveness and accessibility of their therapies without grappling with the complexities of manufacturing and logistics themselves. The crux of Catalent’s business model lies in enabling its clients to bring medical innovations to market effectively and efficiently. By leveraging its expertise in areas such as oral, injectable, and inhalable delivery forms, Catalent ensures that drugs are not only manufactured to the highest standards but are also optimized for patient adherence and effectiveness. The company earns its revenues through long-term contracts by offering continuous support from the early stages of drug development through to commercialization. Catalent drives its growth by staying ahead of industry trends, investing heavily in biologics and gene therapy, which represent high-growth areas in the pharmaceutical industry, thereby ensuring its relevance and significance in an ever-evolving healthcare landscape.

CTLT Intrinsic Value
56.41 USD
Overvaluation 11%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-9.3%
=
Net Income
-413m
/
Revenue
4.4B
What is the Net Margin of Catalent Inc?

Based on Catalent Inc's most recent financial statements, the company has Net Margin of -9.3%.

Back to Top